C. difficile-Associated Diarrhea Incidence & Outcomes in Physician Office Infusion Centers
February 26, 2013
SAN DIEGO, CA (October 19, 2012) – A retrospective review of 1,352 patients treated at nine Infectious Disease POICs with intravenous antibiotics (IVAB) from January 1 to June 30, 2011, was conducted to assess the reduced risk level of developing health care facility-associated Clostridium difficile (CDI) in a POIC and the decreased incidence of recurrence. During the 6-month study period, 1,352 patients were treated in the POIC with outpatient IVAB. Fourteen cases (1%) were identified with confirmed or suspected CDI. All were documented and categorized as associated with community onset-health facility or indeterminate. The incidence of CDI for patients treated at POICs was 2.9 per 10,000 patient-days versus the national average of 8.3 per 10,000 patient-days. Successful outcomes were achieved in all but one patient who was lost to follow up (93%). No recurrences were observed after 90 days. Most prescribed IVABs associated with CDI were ceftriaxone (36%), vancomycin (36%) and piperacillin-tazobactam (29%). Third- and fourth-generation cephalosporins were used in 8 of 14 patients overall (57%). Rates of CDI were low in patients receiving IVAB at POICs. Treatment of CDI was successful with no recurrence in the POIC setting, even with health-care facility associated onset. This study further validates the safety of transitioning appropriate patients from an inpatient setting to a POIC for continued IVAB therapy.
This study was presented at the 1st annual IDWeek™. For a printed copy of this research poster study, please call 1.866.654.2451 or email firstname.lastname@example.org.
ABOUT HEALIX®, INC.
Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.
ABOUT IDWeek 2012
IDWeek 2012 is the first joint annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). With the theme—Advancing Science, Improving Care—IDWeek will feature the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2012 took place October 17-21 at the San Diego Convention Center in San Diego, California.
For more information, visit www.idweek.org.
Lucinda J. Van Anglen, PharmD